Semi-automated risk estimation using large databases: Quinolones and clostridium difficile associated diarrhea

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 6, 2010, Pages 610-617

  Mera, Robertino M ^a   Beach, Kathleen J ^a   Powell, Gregory E ^a   Pattishall, Edward N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antibiotics; Epidemiology; Quinolones

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOMATION; BILLING AND CLAIMS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; DATABASES, FACTUAL; DIARRHEA; ELECTRONIC HEALTH RECORDS; FEMALE; FLUOROQUINOLONES; HUMANS; INCIDENCE; MACROLIDES; MALE; MIDDLE AGED; POISSON DISTRIBUTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77953492069     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1968     Document Type: Article

References (29)

1. Kelly CP, Pothoulakis C, LaMont JT., Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262.
2. Wistrom J, Norrby SR, Myrhe EB et al. Frequency of antibioticassociated diarrhoea in 2642 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50. (Pubitemid 32058754)
3. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ., Implications of the changing face of Clostridium difficile disease for healthcare practitioners. Am J Infect Control 2007; 35: 237-253.
4. McFarland LV., Renewed interest in a diffcult disease: Clostridium difficile infections - epidemiology and current treatment strategioes. Curr Opin Gastroenterol 2008; 25: 24-35.
5. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-472.
6. Dubberke EF, Reske KA, Noble-Wang J, et al. Prevalence of C. difficile environmental contamination and strain variability in multiple healthcare facilities. Am J Infect Control 2007; 35: 315-318.
7. Tedesco FJ, Barton RW, Alpers DH., Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974; 81: 429-33.
8. Gerding DN., Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38: 646-648.
9. Thomas C, Stevenson M, Riley TV., Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-1350.
10. McFarland LV, Surawicz CM, Stamm, WE., Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients J Infect Dis 1990; 162: 678-684.
11. Chang, V.T., Nelson, K., (2000) The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000; 31: 717-722.
12. Owens JRC, Donskey CJ, Gaynes RP et al. Antimicrobial associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1 S19-S31.
13. Yip C, Loeb M, Salama S et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001; 22: 572-575. (Pubitemid 33104885)
14. Golledge CL, Carson CF, O'Neill GL et al. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1992; 30: 141-148.
15. McCusker ME, Harris AD, Perencevich E et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9: 730-733. (Pubitemid 36676373)
16. Gaynes R, Rimland D, Killum E et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38: 640-645. (Pubitemid 38333858)
17. Marelli C., Cload P., Ross S., Kallenbh L., Haas S., Gunnarsson C., Using electronic medical records to identify undiagnosed diabetes mellitus in primary care practices. Value Health 2009; 12: A234.
18. Vekeman F., McKenzie R.S., Bookhart B.K., et al. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managedcare database. J Med Econ 2009; 12: 1-8.
19. Pesquita C., Faria D., Falcão A.O., Lord P., Couto F.M., Semantic similarity in biomedical ontologies. PLoS Comput Biol 2009; 5: 7.
20. http://www.fda.gov/Medwatch/report/meddra.htm [accessed on 3/16/2009].
21. http://www.ihtsdo.org/ [accessed on 3/16/ 2009].
22. Seeger JD, Williams PL, Waker AM., An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005; 14: 465-476.
23. Petri H, Urquhart J., Channeling bias in the interpretation of drug effects. Stat Med 2006; 10: 577-581.
24. Frome EL., The analysis of rate using poisson regression models. Biometrics 1983; 39: 665-674.
25. Zilberberg MD, Shorr AF, Kollef MH., Increase in adult Clostridium difficile related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-931.
26. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
27. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S., Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179: 767-772.
28. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D., Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33-38.
29. Cunningham R, Dale B, Undy B, Gaunt N., Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-245.